In cancer cells, low concentrations of compound 55 (12.5–100 nM) augmented intracellular ROS and MDA levels, depleted intracellular GSH, and decreased the expression of GPX4, SLC7A11, and SLC40A1. Here, SLC7A11 is linked to cancer.